Shots:
- Pharmapark to get exclusive rights to commercialize the therapy with a status of a local product & will be responsible for filing the report in Russia and other CIS countries
- The agreement will utilize Pharmapark’s sales and marketing capabilities for the ustekinumab biosimilar program in Russia & other CIS countries. Bio-Thera will lead the development, and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou, China
- Bio-Thera’s BAT2206 has completed a P-I study and is currently being evaluated in a P-III clinical study including patients from China, Russia, and other countries & plans to file for regulatory approval with the NMPA, EMA & FDA
Click here to read the full press release/ article | Ref: Businesswire | Image: Businesswire
The post Bio-Thera Expands its Partnership with Pharmapark to Commercialize BAT2206 (biosimilar, ustekinumab in Russia and other CIS Countries first appeared on PharmaShots.
